Bone carcinoma

Summary

Bone carcinoma (MONDO:0002415) is a cancer (an umbrella term covering 7 Mondo subtypes). A subtype of bone cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bone carcinoma
Mondo ID	MONDO:0002415
DOID	DOID:2762
GARD	0023132
Anatomy (UBERON)	UBERON:0001474
Is cancer (heuristic)	yes

Also known as: bone element carcinoma · carcinoma of bone element

Disease family

This is a subtype of bone cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone carcinoma

Related subtypes (11): bone chondrosarcoma, skull cancer, small cell osteogenic sarcoma, peripheral primitive neuroectodermal tumor of bone, sternum cancer, chest wall bone cancer, adult extraskeletal osteosarcoma, primary bone lymphoma, bone sarcoma, bone marrow cancer, cancer affecting bone of limb skeleton

Subtypes (7): paranasal sinus carcinoma, bone squamous cell carcinoma, adamantinoma, growth hormone-producing pituitary gland carcinoma, osteosarcoma arising in bone Paget disease, pituitary adenocarcinoma, metastatic carcinoma in the bone

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.